Marta Del Pino (Spain)
Hospital Clínic de Barcelona Gynecology Oncology Unit. Obstetrics and Gynecology Department
Presenter of 4 Presentations
Introduction by Chairs (ID 1712)
Session Time
15:30 - 16:55
Session Type
Interdisciplinary
Lecture Time
15:30 - 15:33
What messages are important for HPV positive screened women (ID 36)
Session Time
13:30 - 14:55
Session Type
Clinical Science
Lecture Time
13:53 - 14:13
MRNA BIOMARKER IN ANAL CYTOLOGY: A FEASIBLE APPROACH FOR ANAL CANCER SCREENING IN MEN WHO HAVE SEX WITH MEN LIVING WITH HIV (ID 1087)
Session Time
10:00 - 17:00
Session Type
Poster Viewing - 20-24 July
Session Name
Clinical Research / Diagnosis and Management of Anal Cancer and Its’ Precursors
Lecture Time
10:02 - 10:03
Introduction
There is growing interest in anal cancer screening strategies. However, cytological/molecular evaluation of anal samples is challenging. We aimed to determine the feasibility of detecting, in anal liquid-based cytologies, the expression of biomarkers involved in the cell cycle disturbance elicited by human papillomavirus (HPV). The accuracy of this approach in the identification of high-grade squamous intraepithelial lesions/anal intraepithelial neoplasia grade2-3 (HSIL/AIN2-3) was also evaluated. 215 anal cytologies from men having sex with men living with human immunodeficiency virus were evaluated.
Methods
For this cross-sectional study, anal cytology samples, collected in the Anal Cancer Prevention Unit from January to December 2016 from men who have sex with men living with HIV, were retrieved from the Department of Pathology of the Hospital Clinic. Patients showing concordant cytological and anoscopy-directed biopsy diagnosis were selected: 70 with negative cytology and HPV test, 70 with low-grade SIL (LSIL/AIN1) cytology and biopsy, and 75 with cytology and biopsy of HSIL/AIN2-3. CDKN2A/p16, MKI67 and TOP2A mRNA expression was analyzed. HPV detection was performed with Xpert HPV Assay (Cepheid, Sunnyvale, CA). The data were analyzed with the SPSS program (Version 24.0).
Results
The mRNA expression was significantly higher in HSIL compared with LSIL and negative samples for the three biomarkers: TOP2A (p= 0.043 and p=0.030, respectively), MKI67 (p=0.011 and p<0.001, respectively) and CDKN2A/p16 (p=0.011 and p<0.001, respectively). The specificity for HSIL/AIN2-3 detection for a sensitivity established at 70% was 44.7% (95%confidence interval [CI] 36.5-53.2) for TOP2A and MKI67 and 54.5% (95%CI 46.0-62.8%) for CDKN2A/p16.
Conclusions
mRNA detection of cell biomarkers in anal liquid-based cytology is feasible. Further studies are warranted to confirm if strategies based on mRNA detection have any role in anal cancer screening.
This work was supported by the Instituto de Salud Carlos III (ICSIII)-Fondo de Investigación Sanitaria and ERDF ‘One Way to Europe’ (grants PI15/00546 and PI17/00772).
Hide
BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA (ID 1088)
Session Time
12:35 - 14:05
Session Type
Clinical Science Oral Session
Lecture Time
13:14 - 13:26
[{"name":"BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA \u003Csmall\u003E(ID 1088)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1088,"presentation":"BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA \u003Csmall\u003E(ID 1088)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Marta Del Pino (Spain)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/76.jpg"},"playlist":[{"name":"BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASI","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/1088 BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/1088 BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/34916072.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/1088 BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA.vtt"}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"aE22UU0jL"}
[session]
[presentation]
[presenter]
Hide
Moderator of 2 Sessions
Session Type
Interdisciplinary
Session Time
15:30 - 16:55
Session Type
Clinical Science Oral Session
Session Time
08:30 - 09:20
[{"name":"YIELD OF LOOP ELECTROSURGICAL EXCISION PROCEDURE (LOOP) AMONG PATIENTS WITH AND WITHOUT KNOWN HIGH GRADE CERVICAL DYSPLASIA \u003Csmall\u003E(ID 983)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":983,"presentation":"YIELD OF LOOP ELECTROSURGICAL EXCISION PROCEDURE (LOOP) AMONG PATIENTS WITH AND WITHOUT KNOWN HIGH GRADE CERVICAL DYSPLASIA \u003Csmall\u003E(ID 983)\u003C\/small\u003E","session":"Oral Session 8: Screening and Management Cervix Lesions","presenter":"Shuk On Annie A. Leung (United States of America)","photo":""},"playlist":[{"name":"YIELD OF LOOP ELECTROSURGICAL EXCISION PROCEDURE (LOOP) AMONG PATIENTS WITH AND WITHOUT KNOWN HIGH G","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/Shuk On Annie Leung_983_1010_YIELD OF LOOP ELECTROSURGICAL.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/79\/Shuk On Annie Leung_983_1010_YIELD OF LOOP ELECTROSURGICAL.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/C0D91A2.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/Shuk On Annie Leung_983_1010_YIELD OF LOOP ELECTROSURGICAL.vtt"}]},{"name":"INTERNATIONAL QUALITY ASSURANCE OF HPV DNA GENOTYPING SERVICES: THE 2019 GLOBAL HPV DNA PROFICIENCY STUDY \u003Csmall\u003E(ID 771)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":771,"presentation":"INTERNATIONAL QUALITY ASSURANCE OF HPV DNA GENOTYPING SERVICES: THE 2019 GLOBAL HPV DNA PROFICIENCY STUDY \u003Csmall\u003E(ID 771)\u003C\/small\u003E","session":"Oral Session 8: Screening and Management Cervix Lesions","presenter":"Joakim Dillner (Sweden)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/77.jpg"},"playlist":[{"name":"INTERNATIONAL QUALITY ASSURANCE OF HPV DNA GENOTYPING SERVICES: THE 2019 GLOBAL HPV DNA PROFICIENCY ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/part 1-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/79\/part 1-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/2033BB09.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/part 1-0.vtt"}]},{"name":"FIRST-VOID URINE AS AN ALTERNATIVE TO PHYSICIAN-TAKEN SAMPLES FOR HPV SCREENING \u003Csmall\u003E(ID 1269)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1269,"presentation":"FIRST-VOID URINE AS AN ALTERNATIVE TO PHYSICIAN-TAKEN SAMPLES FOR HPV SCREENING \u003Csmall\u003E(ID 1269)\u003C\/small\u003E","session":"Oral Session 8: Screening and Management Cervix Lesions","presenter":"Michelle Laeremans (Belgium)","photo":""},"playlist":[{"name":"FIRST-VOID URINE AS AN ALTERNATIVE TO PHYSICIAN-TAKEN SAMPLES FOR HPV SCREENING","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/Michelle Laeremans - IPVC20 1269 FIRST-VOID URINE AS AN ALTERNATIVE TO PHYSICIAN-TAKEN SAMPLES FOR HPV SCREENING 001.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/79\/Michelle Laeremans - IPVC20 1269 FIRST-VOID URINE AS AN ALTERNATIVE TO PHYSICIAN-TAKEN SAMPLES FOR HPV SCREENING 001.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/56C0523B.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/Michelle Laeremans - IPVC20 1269 FIRST-VOID URINE AS AN ALTERNATIVE TO PHYSICIAN-TAKEN SAMPLES FOR HPV SCREENING 001.vtt"}]},{"name":"CLINICAL EVALUATION OF ALINITY M HR HPV ASSAY IN POPULATION-BASED CERVICAL CANCER SCREENING SETTING \u003Csmall\u003E(ID 940)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":940,"presentation":"CLINICAL EVALUATION OF ALINITY M HR HPV ASSAY IN POPULATION-BASED CERVICAL CANCER SCREENING SETTING \u003Csmall\u003E(ID 940)\u003C\/small\u003E","session":"Oral Session 8: Screening and Management Cervix Lesions","presenter":"Anja Ostrbenk Valencak (Slovenia)","photo":""},"playlist":[{"name":"CLINICAL EVALUATION OF ALINITY M HR HPV ASSAY IN POPULATION-BASED CERVICAL CANCER SCREENING SETTING","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/Anja Ostrbenk Valencak IPVC20 940.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/79\/Anja Ostrbenk Valencak IPVC20 940.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/3816ABF5.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/79\/Anja Ostrbenk Valencak IPVC20 940.vtt"}]}]
{"type":2,"code":"7E32UU02n"}
[session]
[presentation]
[presenter]